<DOC>
	<DOCNO>NCT00002870</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining chemotherapy peripheral stem cell transplantation may allow doctor give high dos chemotherapy drug kill tumor cell . It yet know high dose chemotherapy plus peripheral stem cell transplantation effective standard therapy breast cancer . PURPOSE : Randomized phase III trial compare effectiveness high dose chemotherapy plus peripheral stem cell transplantation standard therapy treat woman locally recurrent metastatic breast cancer .</brief_summary>
	<brief_title>High Dose Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Standard Therapy Treating Women With Locally Recurrent Metastatic Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate effect 3-year survival intensive chemotherapy cyclophosphamide/thiotepa peripheral blood stem cell rescue woman locally recurrent metastatic breast cancer respond induction therapy epirubicin/fluorouracil/cyclophosphamide . II . Evaluate effect intensive treatment patient quality life . III . Evaluate tumor response progression-free survival intensification . OUTLINE : This randomize study . Patients stratify clinical/therapeutic hormone sensitivity participate institution . All patient receive induction therapy epirubicin , fluorouracil , cyclophosphamide ( FEC 100 ) every 3 week 4 course , response evaluate least 2 course . Patients complete response least 50 % partial response randomize either therapy receive intensification chemotherapy . Patients randomized intensification undergo peripheral blood stem cell ( PBSC ) harvest G-CSF mobilization third fourth induction course . Three 6 week induction , patient receive intensification chemotherapy cyclophosphamide/thiotepa follow PBSC . Post-transplant G-CSF give hematopoietic support . No concurrent hormonal therapy permit induction ; local irradiation multifocal tumor allow provide response still evaluable . Local therapy ( excision single metastasis , radiotherapy metastatic site ) permit completion protocol therapy . Treatment relapse disease discretion investigator . Patients follow every 3 month 3 year relapse , every 6 month . PROJECTED ACCRUAL : A total 180 patient accrue 3 year multicenter study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically proven glandular breast cancer Metastatic locoregionally relapse disease curative surgery and/or radiotherapy feasible Histologic/cytologic confirmation metastasis feasible Progression require within month prior entry , whether occurs hormonal therapy No clinically detectable cerebral meningeal involvement Measurable lesion require , include soft tissue site , lymphadenopathy , visceral site The following consider measurable : Bony sit involvement Ascites Pulmonary lymphangitic carcinomatosis Skin lesion Pathologic CEA CA 15.3 level Laboratory change Pleural effusion Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : Under 60 Sex : Women Menopausal status : Not specify Performance status : WHO 02 Life expectancy : Greater 3 month Hematopoietic : ANC least 2,000 Platelets least 100,000 Hepatic : Bilirubin great 2.0 mg/dL ( 35 micromoles/L ) Renal : Creatinine great 1.3 mg/dL ( 130 micromoles/L ) Cardiovascular : No congestive heart failure , even stable No coronary artery disease No myocardial infarction within 6 month Ventricular ejection fraction ( rest ) normal isotopic scan echocardiogram No evidence cardiac disease EKG Other : No active infection No second malignancy except : In situ cervical carcinoma Basal cell skin carcinoma No pregnant woman No psychological , familial , social , geographical contraindication regular followup PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior palliative chemotherapy At least 1 year since adjuvant chemotherapy Maximum prior cumulative anthracycline dose follow : Epirubicin great 450 mg per square meter Doxorubicin great 300 mg per square meter Pirarubicin great 300 mg per square meter Mitoxantrone great 60 mg per square meter Endocrine therapy : Prior hormonal therapy allow See Disease Characteristics Radiotherapy : At least 6 week since radiotherapy one third hematopoietic region Surgery : Not specify</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>stage IV breast cancer</keyword>
	<keyword>recurrent breast cancer</keyword>
</DOC>